The party over for Neothetics Inc. (NASDAQ:NEOT)?

834

Shares of Neothetics, Inc. (NASDAQ:NEOT) last traded at $0.71. (NASDAQ:NEOT) performance year to date is -36.86%. The 200 day simple moving average is -52.97%. The 200 SMA is considered a major indicator by market analysts and traders for determining the long-term trend. The price in the market that coincides with the 200 day SMA is recognized as a key support when price moves above the 200 day SMA or resistance when price drops below the same.

Neothetics, Inc. is a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market. The Company is focused on localized fat reduction and body contouring. Its lead product candidate, LIPO-202, is for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. The Company is also developing LIPO-102 for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye. Neothetics, Inc. is headquartered in San Diego, California.

Neothetics, Inc. (NASDAQ:NEOT) has been in the buzz for all the right reasons.

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The Exponential Moving Average is similar to a simple moving average but it uses a weighting element that exponentially drops from the recent data point. EMA analysis assesses the short term,5 days and 13 days, intermediate term that is 20 days and long-term 50 days EMA. These EMAs will give bullish indications when moving above trailing EMAs and below the latest price and vice versa. EMA alerts comprise crossovers that is the 5 day EMA crosses below/above the 20 day EMA and EMA convergences, 5 day EMA comparable to 13 day EMA. The 5 day EMA 1.72 is higher than the last trade price suggesting a short term bearish pattern building up. Long term, the 50 day EMA 2.00 is also higher than the current trading price depicting a bearish trend overall..

The relative strength index is a momentum oscillator that can measure the magnitude of stock price and velocity changes. Momentum is computed as the ratio of plus price changes to negative price changes. The RSI assessment compares the prevailing RSI against oversold (30), overbought (70) and neutral (50) conditions. Alerts will apprise you when stocks retreat from overbought/oversold levels or breakthrough neutral (50). The current RSI is 21.92 suggesting a bearish price action.

Neothetics, Inc. (NASDAQ:NEOT) is all set to report its earnings on May 11/b. As per Zack’s analyst scores, Neothetics, Inc. (NASDAQ:NEOT) currently has a mean brokerage rating of . On a scale of 1-5, a rating of 1 or 2 would imply a buy, and a rating of 4 or 5 would indicate a sell recommendation. A rating of 3 would represent a hold on the equity. The consensus target price on (NASDAQ:NEOT) is $ with a high of $ and a low of $.

As such, while we consider Neothetics, Inc. (NASDAQ:NEOT) represents a enthralling growth story open to several attractive markets, it would be fascinating to see how it works for long-term shareholders.

Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced top-line safety and efficacy results from its Phase 2 proof-of-concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat. LIPO-202 did not demonstrate improvement on any efficacy measurements or separation from placebo. LIPO-202 continued to show a benign safety profile.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.